AbbVie Inc. — Form 8-K summary
Reporting date: October 5, 2026. This current report updates expected third-quarter and full-year 2026 adjusted diluted EPS to reflect acquired in-process research and development (IPR&D) and milestones expense. Third-quarter results remain preliminary and have not been finalized.
Financial information and guidance
| Metric | Reported information |
|---|---|
| Q3 2026 acquired IPR&D and milestones expense | $216 million pre-tax; expected to reduce GAAP and adjusted diluted EPS by $0.11 each. |
| Q3 2026 adjusted diluted EPS guidance | $3.73–$3.77, including the expense. |
| FY 2026 adjusted diluted EPS guidance | $13.76–$13.96, including the Q3 expense. |
The filing does not provide revenue, finalized profit, cash flow, margins, debt, or liquidity figures.
Change from prior guidance
Guidance announced July 31, 2026 excluded acquired IPR&D and milestones expense that might be incurred after Q2. The updated full-year range incorporates the Q3 expense; the filing does not quantify a separate change to the guidance range beyond that inclusion.
Outlook, risks, and qualifications
AbbVie says it does not forecast acquired IPR&D and milestones expense because the occurrence and timing of collaborations, licensing agreements, and asset acquisitions are uncertain. Q3 results are subject to financial-statement closing procedures and may differ from these preliminary estimates.
The company identifies risks including intellectual-property challenges, product competition, R&D difficulties, litigation or government action, regulatory changes, macroeconomic uncertainty, international conflict, trade disputes, tariffs, and risks of global operations. The report’s information is furnished and generally is not deemed “filed” for Exchange Act Section 18 purposes.
Investor items to verify
- Final Q3 results and whether the $216 million expense and $0.11 per-share impact match the preliminary estimate.
- Whether AbbVie maintains or revises the stated Q3 and full-year adjusted EPS guidance ranges.
- Any additional acquired IPR&D or milestone expenses and their effect on GAAP and adjusted results.
- Revenue, cash flow, debt, liquidity, and other operating results in the company’s subsequent earnings release or periodic filings.